

February 25, 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740



RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS TO STATE OF THE STAT
Enzymatic Therapy, Inc.	Cell Forte® Max <sup>3</sup>	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	Targeted 3-Level Support to Boost the Body's Natural Defenses*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

Title: Senior Vice President of Scientific Affairs

Date: 2/25/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Michael P. Devereux Chief Financial Officer

975 0162

LET /1577

825 Challenger Drive Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Cell Forte Max3 31e